Consistent reduction in the annualized rate of brain volume loss across phase 3 core and extension trials of fingolimod in relapsing multiple sclerosis.
Radue E, Sprenger T, Chin P, Meier DP, Sfikas N, Barkhof F
Mult Scler Relat Disord. 2014 Nov; 3(6):750-1. Epub 2014 Nov 21. PMID: 25891586.Abstract